Fosun Announces $628 Million Deal for Majority Stake in Chengdu Antejin
publication date: Oct 27, 2021
Shanghai Fosun Pharma announced a $628 million deal to acquire a 73% stake in Chengdu Antejin Biotech, a vaccine company. Fosun paid $174 million to nine Antejin shareholders, and it contributed its own vaccine subsidiary, Dalian Aleph Biomedical at a value of $454 million, for the remainder. Antejin is developing a 13-valent pneumonia vaccine intended for infants, a competitor to Pfizer’s Prevnar 13. In the US, Pfizer’s Prevnar 20 was recently approved to launch while Antejin is developing a 24-valent pneumonia conjugate candidate. More details.....
Stock Symbols: (SHA: 600196; HK: 02196)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.